What are the key differences in the history and physical examination between acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)?

Key Differences in History and Physical Examination Between AML and CML

AML typically presents acutely with symptoms of bone marrow failure (fatigue, bleeding, infections) over days to weeks, while CML presents insidiously over months to years, often discovered incidentally on routine blood work, with 40-50% of patients being completely asymptomatic at diagnosis.

Clinical Presentation Timeline

AML - Acute Onset

• Symptom duration: Days to weeks before diagnosis
• History of preceding symptoms: Fatigue, bleeding, or recurrent infections for ≥1 month may suggest secondary AML or antecedent myelodysplastic syndrome 1
• Acute deterioration: Patients typically present with rapidly progressive symptoms requiring urgent evaluation

CML - Chronic/Insidious Onset

• Symptom duration: Months to years, with chronic phase lasting 2-6 years 2
• Asymptomatic presentation: 40-50% of patients are completely asymptomatic at diagnosis 3, 4
• Incidental discovery: Frequently diagnosed after routine blood examination reveals elevated leukocyte count 2

History-Taking Priorities

AML-Specific History

• Prior exposures: Carefully document exposure to alkylating agents, topoisomerase II inhibitors, or radiation therapy (therapy-related AML accounts for 5-20% of cases) 1, 5
• Antecedent hematologic disorders: History of myelodysplastic syndrome or myeloproliferative disorders 1
• Age consideration: Median age 67-71 years, with 54% diagnosed ≥65 years 5
• Ethnicity: Document race/ethnicity as prognostic factor 6

CML-Specific History

• Gradual symptom progression: Weight loss, malaise, left upper quadrant fullness developing over months 4
• Rare manifestations: Gouty arthritis (elevated uric acid), priapism, visual changes (retinal hemorrhages from basophilia) 4
• Median age: 60-65 years at diagnosis 3

Physical Examination Findings

AML Physical Findings

• Signs of bone marrow failure:
  • Pallor (anemia)
  • Petechiae, ecchymoses (thrombocytopenia) 1
  • Fever, signs of infection (neutropenia)
• Organomegaly: Less prominent; hepatosplenomegaly uncommon
• Extramedullary disease: Rare but includes:
  • Skin infiltration (leukemia cutis)
  • Gingival hypertrophy (monocytic subtypes)
  • Lymphadenopathy (uncommon) 5, 6
  • CNS involvement (requires specific evaluation if symptomatic) 5

CML Physical Findings

• Splenomegaly: Most consistent finding, present in 40-50% of chronic phase cases 3, 4
• Hepatomegaly: Less common than splenomegaly 4
• Absence of lymphadenopathy: Extramedullary infiltration (apart from liver/spleen) is rare in chronic phase 4
• Leukostatic symptoms: Uncommon despite WBC often >100 × 10⁹/L (priapism, dyspnea, confusion) 4

Disease Phase Recognition

AML Presentation

• Single acute phase: No preceding chronic phase
• Blast percentage: ≥20% blasts in peripheral blood or bone marrow (WHO criteria) 1
• Rapid clinical deterioration: Requires urgent intervention

CML Presentation Phases

• Chronic phase (90-95% at diagnosis):

  • <15% blasts 4
  • Minimal symptoms or asymptomatic
  • Splenomegaly common

• Accelerated phase (if present at diagnosis):

  • 15-29% blasts 3
  • Increasing basophils (>20%)
  • Progressive splenomegaly despite therapy

• Blast phase/crisis (rare at diagnosis, <5%):

  • ≥30% blasts (traditional criteria) 3
  • Resembles acute leukemia clinically 7, 2

Critical Distinguishing Features

Symptom Tempo

• AML: Acute, rapidly progressive over days-weeks
• CML: Insidious, gradual over months-years or asymptomatic

Splenomegaly

• AML: Uncommon, not a prominent feature
• CML: Present in 40-50%, most consistent physical finding 3, 4

Constitutional Symptoms

• AML: Acute fatigue, bleeding, fever from infections
• CML: Gradual weight loss, early satiety (from splenomegaly), malaise 4

Common Pitfall

The major diagnostic pitfall is CML presenting in blast crisis, which can be morphologically and clinically indistinguishable from de novo AML 8, 9. In such cases:

• Cytogenetic screening for Philadelphia chromosome is essential 8
• BCR::ABL1 testing by RT-PCR or FISH is diagnostic 10
• This distinction has critical therapeutic implications (TKI therapy vs. intensive chemotherapy)